{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T02:16:36Z","timestamp":1785291396996,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.clgc.2017.09.001","type":"journal-article","created":{"date-parts":[[2017,9,7]],"date-time":"2017-09-07T22:46:19Z","timestamp":1504824379000},"page":"e373-e382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)\u2013Deficient Carcinomas of the Urinary\u00a0System"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6271-0831","authenticated-orcid":false,"given":"Sumati","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Albertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gaston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta E.","family":"Heilbrun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Parnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Morgans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Madison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Gowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siraj M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherri Z.","family":"Millis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2017.09.001_bib2","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2017.09.001_bib3","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/annonc\/mdj079","article-title":"Systemic chemotherapy in inoperable or metastatic bladder cancer","volume":"17","author":"Bamias","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2017.09.001_bib4","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/annonc\/mds583","article-title":"Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine\/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16\/03)","volume":"24","author":"Bamias","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2017.09.001_bib5","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2017.09.001_bib6","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer","volume":"34","author":"Massard","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2017.09.001_bib7","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"issue":"suppl","key":"10.1016\/j.clgc.2017.09.001_bib8","article-title":"Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012","volume":"33","author":"Plimack","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2017.09.001_bib9","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2017.09.001_bib10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.clgc.2017.09.001_bib11","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/jclinpath-2016-203650","article-title":"Gene of the month: SMARCB1","volume":"69","author":"Kalimuthu","year":"2016","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.clgc.2017.09.001_bib12","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/ng.2628","article-title":"Proteomic and bioinformatic analysis of mammalian SWI\/SNF complexes identifies extensive roles in human malignancy","volume":"45","author":"Kadoch","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.clgc.2017.09.001_bib13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-pathol-012414-040445","article-title":"SWI\/SNF chromatin remodeling and human malignancies","volume":"10","author":"Masliah-Planchon","year":"2015","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.clgc.2017.09.001_bib14","doi-asserted-by":"crossref","first-page":"e62483","DOI":"10.1371\/journal.pone.0062483","article-title":"ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors","volume":"8","author":"Balb\u00e1s-Martinez","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clgc.2017.09.001_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.humpath.2016.04.006","article-title":"ARID1A alteration in aggressive urothelial carcinoma and variants of urothelial carcinoma","volume":"55","author":"Li","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clgc.2017.09.001_bib16","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1158\/1078-0432.CCR-08-2091","article-title":"Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1\/SMARCB1 in malignant rhabdoid tumors","volume":"15","author":"Jackson","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2017.09.001_bib17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00401-010-0767-x","article-title":"Loss of SMARCB1\/INI1 expression in poorly differentiated chordomas","volume":"120","author":"Mobley","year":"2010","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.clgc.2017.09.001_bib18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/modpathol.2012.175","article-title":"Epithelioid sarcoma is associated with a high percentage of SMARCB1 deletions","volume":"26","author":"Sullivan","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clgc.2017.09.001_bib19","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/PAS.0b013e3182770406","article-title":"Renal medullary carcinoma: molecular, immunohistochemistry, and morphologic correlation","volume":"37","author":"Liu","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2017.09.001_bib20","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/PAS.0000000000000797","article-title":"SMARCB1 (INI-1)-deficient sinonasal carcinoma: a series of 39 cases expanding the morphologic and clinicopathologic spectrum of a recently described entity","volume":"41","author":"Agaimy","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2017.09.001_bib21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.prp.2009.01.003","article-title":"Pediatric extra-renal rhabdoid tumors with unusual morphology: a diagnostic pitfall for small biopsies","volume":"205","author":"Alaggio","year":"2009","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.clgc.2017.09.001_bib22","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/cncr.29826","article-title":"Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations","volume":"122","author":"Ross","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2017.09.001_bib23","doi-asserted-by":"crossref","unstructured":"Gupta S, Greenberg S, Grimmett J, et\u00a0al. Inherited DNA repair gene mutations detected by tumor next generation sequencing in urinary tract cancers [e-pub ahead of print]. Fam Cancer, http:\/\/dx.doi.org\/10.1007\/s10689-017-9980-2, accessed May 1, 2017.","DOI":"10.1007\/s10689-017-9980-2"},{"key":"10.1016\/j.clgc.2017.09.001_bib24","first-page":"615895","article-title":"Renal medullary carcinoma: case report of an aggressive malignancy with near-complete response to dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy","volume":"2014","author":"Amjad","year":"2014","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.clgc.2017.09.001_bib25","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.urology.2008.05.009","article-title":"High-dose-intensity MVAC for advanced renal medullary carcinoma: report of three cases and literature review","volume":"72","author":"Rathmell","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2017.09.001_bib26","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/ng.3581","article-title":"Landscape of tumor-infiltrating T cell repertoire of human cancers","volume":"48","author":"Li","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.clgc.2017.09.001_bib27","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/neuonc\/nov264","article-title":"Atypical teratoid\/rhabdoid tumors\u2014current concepts, advances in biology, and potential future therapies","volume":"18","author":"Fr\u00fchwald","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.clgc.2017.09.001_bib28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/gcc.22018","article-title":"High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid\/rhabdoid tumors","volume":"52","author":"Hasselblatt","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.clgc.2017.09.001_bib29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ccell.2016.02.001","article-title":"Atypical teratoid\/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes","volume":"29","author":"Johann","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clgc.2017.09.001_bib30","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.cancergen.2014.04.004","article-title":"Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth","volume":"207","author":"Kim","year":"2014","journal-title":"Cancer Genet"},{"key":"10.1016\/j.clgc.2017.09.001_bib31","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cancergen.2014.09.002","article-title":"Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor","volume":"207","author":"Hu","year":"2014","journal-title":"Cancer Genet"},{"key":"10.1016\/j.clgc.2017.09.001_bib32","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1073\/pnas.0913297108","article-title":"Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1","volume":"108","author":"Smith","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clgc.2017.09.001_bib33","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1158\/0008-5472.CAN-10-2167","article-title":"Aurora A is a repressed effector target of the chromatin remodeling protein INI1\/hSNF5 required for rhabdoid tumor cell survival","volume":"71","author":"Lee","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2017.09.001_bib34","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1096\/fj.06-7082com","article-title":"Inhibition of a protein-protein interaction between INI1 and c-Myc by small peptidomimetic molecules inspired by Helix-1 of c-Myc: identification of a new target of potential antineoplastic interest","volume":"21","author":"Bagnasco","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.clgc.2017.09.001_bib35","doi-asserted-by":"crossref","first-page":"e77652","DOI":"10.1371\/journal.pone.0077652","article-title":"Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors","volume":"8","author":"W\u00f6hrle","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clgc.2017.09.001_bib36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ng.3746","article-title":"SMARCB1-mediated SWI\/SNF complex function is essential for enhancer regulation","volume":"49","author":"Wang","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.clgc.2017.09.001_bib37","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2014.07.018","article-title":"Vulnerabilities of mutant SWI\/SNF complexes in cancer","volume":"26","author":"Helming","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clgc.2017.09.001_bib38","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1371\/journal.pbio.0060113","article-title":"Polycomb group genes: keeping stem cell activity in balance","volume":"6","author":"Sauvageau","year":"2008","journal-title":"PLoS Biol"},{"key":"10.1016\/j.clgc.2017.09.001_bib39","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ccr.2010.09.006","article-title":"Epigenetic antagonism between polycomb and SWI\/SNF complexes during oncogenic transformation","volume":"18","author":"Wilson","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clgc.2017.09.001_bib40","doi-asserted-by":"crossref","first-page":"7922","DOI":"10.1073\/pnas.1303800110","article-title":"Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2","volume":"110","author":"Knutson","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clgc.2017.09.001_bib41","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/neuonc\/nos285","article-title":"Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells","volume":"15","author":"Alimova","year":"2013","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.clgc.2017.09.001_bib42","doi-asserted-by":"crossref","first-page":"e0158888","DOI":"10.1371\/journal.pone.0158888","article-title":"Preclinical evidence of anti-tumor activity induced by EZH2 inhibition in human models of synovial sarcoma","volume":"11","author":"Kawano","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.clgc.2017.09.001_bib45","author":"Italiano"},{"issue":"suppl","key":"10.1016\/j.clgc.2017.09.001_bib46","article-title":"Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950)","volume":"35","author":"Gounder","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2017.09.001_bib47","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1158\/1078-0432.CCR-15-2260","article-title":"Low-dose histone deacetylase inhibitor treatment leads to tumor growth arrest and multi-lineage differentiation of malignant rhabdoid tumors","volume":"22","author":"Muscat","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2017.09.001_bib48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00428-016-1977-y","article-title":"Loss of expression of the SWI\/SNF complex is a frequent event in undifferentiated\/dedifferentiated urothelial carcinoma of the urinary tract","volume":"469","author":"Agaimy","year":"2016","journal-title":"Virchows Arch"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767317302768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767317302768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:28:08Z","timestamp":1761564488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767317302768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1558767317302768"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2017.09.001","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)\u2013Deficient Carcinomas of the Urinary\u00a0System","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2017.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}